80 new oncology drugs have been approved since 2018, with targeted therapy accounting for the bulk of these new drugs
2022 saw fewer approvals than in recent years, but a more diverse set of approaches and MOAs were approved in 2022 and are "on deck" (positive pivotal data) in 2023
Implications of the Inflation Reduction Act (IRA) and recent FDA guidance around accelerated approval portend changes to the "fast-to-market" imperative
Pulses are our e-newsletters that look at recent trends and promising directions across life sciences. Add your name to our mail list to receive future updates.
Bluestar BioAdvisors, LLC
521 Fifth Avenue, 25th Floor
New York, NY USA 10175
